(:CELG)
Business Focus: N/A
Dec 01, 2021 11:16 pm ET
INVESTOR ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action Lawsuits filed on behalf of BMY, LSPD, PTON, ZG Investors, Lead Plaintiff Deadlines Set
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Bristol-Myers Squibb Company (BMY)Class: Investors...
Nov 30, 2021 11:34 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of BMY, CTXS, HEPS and STNE
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. Bristol-Myers Squibb Company (BMY)Class: Investors who received Contingent Value Rights (“CVRs”) (BMY.RT) in...
Nov 18, 2021 09:50 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of Bristol-Myers Squibb Company - BMY
CEDARHURST, N.Y., Nov. 18, 2021 /PRNewswire/ -- The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of Bristol-Myers Squibb Company ("BMS" or "the Company") (NYSE: BMY), if they received Contingent Value Rights ("CVRs") (NYSE: BMY.RT) in exchange for their shares of Celgene Corporation (NASDAQ: CELG) pursuant to BMS' acquisition of Celgene on November 20, 2019. Shareholders have until December 6, 2021 to file lead plaintiff applications in the securities class action lawsuit.
Nov 17, 2021 06:38 pm ET
BRISTOL MYERS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Bristol-Myers Squibb Company - BMY
NEW ORLEANS, Nov. 17, 2021 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until December 6, 2021 to file lead plaintiff applications in a securities class action lawsuit against Bristol-Myers Squibb Company ("BMS" or "the Company") (NYSE: BMY), if they received Contingent Value Rights ("CVRs") (NYSE: BMY.RT) in exchange for their shares of Celgene Corporation (NASDAQ: CELG) pursuant to BMS' acquisition of Celgene on November 20, 2019. This action is pending in the United States District Court for the Southern District of New York.
Dec 16, 2019 07:30 am ET
NexImmune Appoints Sol Barer as Chairman of the Board of Directors
NexImmune, a clinical-stage biopharmaceutical company developing novel immune-therapeutics based on a proprietary Artificial Immune Modulation (AIM) nanotechnology platform, announced that Sol Barer, PhD has been appointed as the Company’s Chairman...
Nov 20, 2019 04:18 pm ET
Celgene Announces Plans to Transfer Listing of Celgene’s Contingent Value Rights Following Closing of Acquisition by Bristol-Myers Squibb
Celgene Corporation (NASDAQ: CELG) announced today that following the completion of Celgene’s acquisition by Bristol-Myers Squibb Company (NYSE: BMY), Bristol-Myers Squibb and Celgene plan to transfer the listing of Celgene’s contingent value rights (NASDAQ: CELGZ) (“Celgene CVRs”) that are related to Celgene’s ABRAXANE® product from the NASDAQ Global Market to the New York Stock Exchange (“NYSE”). As a result, Celgene notified the NASDAQ Global Market today of its intent to initiate the voluntary delisting of the Celgene CVRs. The Celgene CVRs are expected to begin trading on the N
Nov 18, 2019 05:10 pm ET
Exelon Corporation to Join the NASDAQ-100 Index Beginning November 21, 2019
Nasdaq (Nasdaq: NDAQ) today announced that Exelon Corporation (Nasdaq: EXC), will become a component of the NASDAQ-100 Index® (Nasdaq: NDX), the NASDAQ-100 Equal Weighted Index (Nasdaq: NDXE) and the NASDAQ-100 Ex-Tech Sector Index (Nasdaq: NDXX)...
Nov 15, 2019 07:30 am ET
Celgene Receives CHMP Positive Opinion for REVLIMID® (lenalidomide) in Combination With Rituximab for the Treatment of Adult Patients With Previously Treated Follicular Lymphoma
Celgene Corporation (NASDAQ:CELG) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the approval of REVLIMID® (lenalidomide) in combination with rituximab (anti-CD20 antibody) (R²) for the treatment of adult patients with previously treated follicular lymphoma (FL) (Grade 1-3a). If approved by the European Commission (EC), R2 will be the first combination treatment regimen for patients with FL that does not include chemotherapy.
Nov 12, 2019 08:00 am ET
Skyhawk Therapeutics Announces a Second Multi-Target Collaboration Agreement with Celgene to Discover and Develop Novel Small Molecules that Modulate RNA Splicing
Celgene to receive exclusive options to license a number of Skyhawk's product candidates directed to multiple high-value autoimmune disorder, oncology, and immuno-oncology targets.
Nov 12, 2019 08:00 am ET
Skyhawk Therapeutics Announces a Second Multi-Target Collaboration Agreement with Celgene to Discover and Develop Novel Small Molecules that Modulate RNA Splicing
Celgene to receive exclusive options to license a number of Skyhawk's product candidates directed to multiple high-value autoimmune disorder, oncology, and immuno-oncology targets.
Nov 08, 2019 12:33 pm ET
FDA Approves REBLOZYL® (luspatercept-aamt) for the Treatment of Anemia in Adults With Beta Thalassemia Who Require Regular Red Blood Cell Transfusions
Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced the U.S. Food and Drug Administration (FDA) has approved REBLOZYL® (luspatercept-aamt) for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions.1 REBLOZYL is not indicated for use as a substitute for RBC transfusions in patients who require immediate correction of anemia.1 REBLOZYL is the first and only FDA-approved erythroid maturation agent, representing a new class of therapy which works by regulating la
Nov 06, 2019 09:06 am ET
Celgene to Present New and Updated Data on Key Hematology Pipeline Therapies at American Society of Hematology (ASH) 2019 Annual Meeting
Celgene Corporation (NASDAQ: CELG) today announced data from nearly 70 Company-sponsored, global alliance and investigator-initiated clinical studies evaluating Celgene’s investigational and approved therapies will be presented at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition, December 7-10, in Orlando, Fla.
Oct 31, 2019 07:30 am ET
Celgene Reports Third Quarter 2019 Operating and Financial Results
Celgene Corporation (NASDAQ: CELG) reported third quarter 2019 total revenue of $4,520 million, a 16 percent increase compared to $3,892 million in the third quarter of 2018.
Oct 16, 2019 06:00 am ET
Celgene and the Multiple Sclerosis Association of America Take the MS MindShift Initiative and “Brain Bulb” Hot Air Balloon to the Sky at Owl-O-Ween Festival to Educate on Multiple Sclerosis and Brain
The MS MindShift: A New View of MS initiative from Celgene Corporation (NASDAQ: CELG) and the Multiple Sclerosis Association of America (MSAA) is making its third stop at the Owl-O-Ween Hot Air Balloon Festival in Kennesaw, Ga., on October 18 and 19. At the festival, the MS MindShift “Brain Bulb” hot air balloon will take flight to raise aw
Sep 20, 2019 07:30 am ET
Celgene Corporation Names Second Round of Celgene Cancer Care Links™ Program Grant Recipients
Celgene Corporation (NASDAQ: CELG) today announced an additional ten programs selected for funding under its Celgene Cancer Care Links™ program, an initiative designed to support healthcare capacity building in resource-constrained countries around the world. The program and initial grants were announced in December 2018.
Sep 12, 2019 04:30 pm ET
Celgene Announces Phase 3 QUAZAR® AML-001 Study of CC-486 as Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Met Primary and Key Secondary Endpoints
Celgene Corporation (NASDAQ: CELG) today announced top-line results from the international phase 3, randomized, double-blind, placebo-controlled study, QUAZAR AML-001. The study evaluated the efficacy and safety of investigational therapy CC-486 as maintenance therapy in patients with newly diagnosed acute myeloid leukemia (AML) who achieved first complete response (CR) or complete response with incomplete blood count recovery (CRi) with induction chemotherapy (with or without consolidation). The study demonstrated that maintenance treatment with CC-486 resulted in a highly statistically signi
Sep 09, 2019 07:30 am ET
Data from Ozanimod Clinical Development Program in Relapsing Forms of Multiple Sclerosis to Be Presented at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
“Celgene is committed to furthering our understanding of multiple sclerosis (MS) and the full potential of ozanimod,” said Terrie Curran, President, Global Inflammation and Immunology, Celgene. “We look forward to sharing these new analyses with the MS community, including data on the long-term efficacy and safety of ozanimod in adults with relapsing forms of MS.”
Aug 26, 2019 06:30 am ET
Amgen To Acquire Otezla® For $13.4 Billion In Cash, Or Approximately $11.2 Billion Net Of Anticipated Future Cash Tax Benefits
THOUSAND OAKS, Calif., Aug. 26, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN) announced today that it has entered into an agreement with Celgene Corporation (NASDAQ: CELG) in connection with its previously announced merger with Bristol-Myers Squibb Company (NYSE: BMY) to acquire worldwide rights to Otezla® (apremilast), the only oral, non-biologic treatment for psoriasis and psoriatic arthritis, and certain related assets and liabilities, for $13.4 billion in cash, or approximately $11.2 billion, net of the present value of $2.2 billion in anticipated future cash tax benefits. Amgen believ
Aug 16, 2019 10:30 am ET
U.S. FDA Approves INREBIC® (Fedratinib) as First New Treatment in Nearly a Decade for Patients With Myelofibrosis
“The approval of INREBIC is another important milestone for Celgene and underscores our commitment to people living with blood cancers,” said Jay Backstrom, M.D., M.P.H., Chief Medical Officer for Celgene. “We are excited to provide INREBIC as a new treatment option that may be used in patients with myelofibrosis, including patients previously treated with ruxolitinib.”
Jul 30, 2019 07:30 am ET
Celgene Reports Second Quarter 2019 Operating and Financial Results
Celgene Corporation (NASDAQ: CELG) reported second quarter 2019 total revenue of $4,400 million, a 15 percent increase compared to $3,814 million in the second quarter of 2018.
Jul 29, 2019 10:10 am ET
Bristol-Myers Squibb Announces European Commission Approval of Pending Acquisition of Celgene
Bristol-Myers Squibb Company (NYSE: BMY) today announced that the European Commission (EC) has granted unconditional approval of Bristol-Myers Squibb’s pending acquisition of Celgene Corporation (NASDAQ:CELG).
Jul 26, 2019 01:24 pm ET
Hach Rose Schirripa & Cheverie LLP Announces $55 Million Settlement in Antitrust Class Action Against Celgene
Hach Rose Schirripa & Cheverie LLP, a nationally recognized plaintiffs’ law firm dedicated to handling complex litigation, announced earlier this week that it has reached a $55 million settlement with Celgene Corporation (NASDAQ: CELG) in a...
Jul 24, 2019 01:30 pm ET
Block & Leviton Announces $55 Million Settlement in Antitrust Case Against Celgene
Block & Leviton LLP, a nationwide plaintiffs’ law firm dedicated to handling complex class action litigation, announced today that it has reached a $55 million settlement with Celgene Corporation (NASDAQ: CELG) in a long-running class action case,...
Jul 24, 2019 07:30 am ET
Celgene and the Multiple Sclerosis Association of America Bring MS MindShift Initiative and “Brain Bulb” Hot Air Balloon to Festival to Raise Awareness of Multiple Sclerosis and Brain Health
Celgene Corporation (NASDAQ: CELG) and the Multiple Sclerosis Association of America (MSAA) are bringing the MS MindShift: A New View of MS initiative to the 37th Annual QuickChek New Jersey Festival of Ballooning in Readington, NJ, on July 26-28, where the MS MindShift “Brain Bulb”
Jul 23, 2019 04:00 pm ET
Jounce Therapeutics Announces Update on Strategic Collaboration with Celgene Corporation
Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced an update on its strategic collaboration with Celgene Corporation...
Jul 19, 2019 01:59 pm ET
FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease
Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behçet’s Disease. OTEZLA, an oral, selective inhibitor of phosphodiesterase 4 (PDE4), is the first and only approved treatment option for oral ulcers associated with Behçet’s Disease, a rare, chronic, multisystem inflammatory disease that is difficult to treat.
Jun 24, 2019 06:59 am ET
Bristol-Myers Squibb Provides Update on Pending Merger with Celgene
Bristol-Myers Squibb Company (NYSE: BMY) today provided an update on the approval process and timeline for the Company’s pending merger with Celgene Corporation (NASDAQ: CELG). The Company remains actively engaged in discussions with the U.S. Federal Trade Commission (“FTC”) on the FTC’s continued review of the proposed transaction. To allow the transaction to close on a timely basis in light of concerns expressed by the FTC, the Company is planning the divestiture of OTEZLA® (apremilast).
Jun 06, 2019 07:30 am ET
US FDA and EMA Accept Applications for Ozanimod for the Treatment of Relapsing Forms of Multiple Sclerosis
Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and
Drug Administration (FDA) has accepted for review the New Drug
Application for ozanimod for the treatment of people with relapsing
forms of multiple sclerosis (RMS) in the United States. The European
Medicines Agency (EMA) also accepted for review the Marketing
Authorization Application for ozanimod for the treatment of adults with
relapsing-remitting multiple sclerosis (RRMS) in the European Union.
Ozanimod is an oral, sphingosine 1-phosphate (S1P) receptor modulator
Jun 05, 2019 06:59 am ET
Bristol-Myers Squibb Announces Post-Closing Leadership Team
Bristol-Myers Squibb Company (NYSE:BMY) today announced the future
leadership team of the combined company effective upon completion of the
company’s pending merger with Celgene Corporation (NASDAQ:CELG).
Jun 04, 2019 11:00 am ET
Celgene Announces Data from Ongoing Studies of Liso-Cel in Patients with Difficult-to-Treat Blood Cancers at ASCO 2019
Celgene Corporation (NASDAQ: CELG) today announced that data from the
TRANSCEND CLL 004 and TRANSCEND NHL 001 trials studying the
investigational anti-CD19 chimeric antigen receptor (CAR) T-cell therapy
lisocabtagene maraleucel (liso-cel; JCAR017) in patients with B-cell
blood cancers were presented at the American Society of Clinical
Oncology (ASCO) Annual Meeting in Chicago.
Jun 04, 2019 07:30 am ET
Celgene Corporation and Acceleron Pharma Announce U.S. FDA Accepts Luspatercept Biologics License Application in Myelodysplastic Syndromes and Beta-Thalassemia
Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ:
XLRN) today announced that the U.S. Food and Drug Administration (FDA)
has accepted Celgene’s Biologics License Application (BLA) for
luspatercept, an investigational erythroid maturation agent, for the
treatment of adult patients with very low to intermediate-risk
myelodysplastic syndromes (MDS)-associated anemia who have ring
sideroblasts and require red blood cell (RBC) transfusions, and for the
treatment of adult patients with beta-thalassemia-associated anemia who
Jun 03, 2019 09:00 am ET
Celgene Updated Analysis of JAKARTA2 Fedratinib Study Shows Clinically Meaningful Responses in Patients Previously Treated for Myelofibrosis with Ruxolitinib
Celgene Corporation (NASDAQ: CELG) announced an updated analysis of data
from the Phase 2 JAKARTA2 clinical study demonstrating clinically
meaningful response rates with investigational fedratinib in patients
with myelofibrosis previously treated with ruxolitinib. This updated
analysis of fedratinib employed intent-to-treat (ITT) principles and
utilized a narrower definition of ruxolitinib relapsed, refractory, or
intolerant patients. Results were shared in a poster presentation today
at the 2019 American Society of Clinical Oncology (ASCO) Annu
Jun 02, 2019 12:45 pm ET
Celgene Presents Data from a Phase 1/2 Clinical Study of Iberdomide in Combination with Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma at ASCO 2019
Celgene Corporation (NASDAQ: CELG) today announced the first clinical
results evaluating iberdomide (CC-220) in combination with dexamethasone
in patients with relapsed and refractory multiple myeloma from the
ongoing phase 1/2 CC-220-MM-001 study during an oral presentation at the
2019 American Society of Clinical Oncology (ASCO) Annual Meeting in
Chicago.
May 28, 2019 12:30 pm ET
FDA Approves REVLIMID® (Lenalidomide) In Combination With Rituximab For the Treatment of Adult Patients with Previously Treated Follicular Lymphoma or Marginal Zone Lymphoma
Celgene Corporation (NASDAQ: CELG) today announced the U.S. Food and
Drug Administration (FDA) approved REVLIMID® (lenalidomide)
in combination with a rituximab product (R²) for the treatment of adult
patients with previously treated follicular lymphoma (FL) or marginal
zone lymphoma (MZL) following Priority Review designation. This is the
first FDA-approved combination treatment regimen for patients with these
indolent forms of non-Hodgkin’s lymphoma (NHL) that does not include
chemotherapy.
May 21, 2019 08:00 am ET
Celgene and the Multiple Sclerosis Association of America Team Up to Launch MS MindShift for Awareness of Multiple Sclerosis and Brain Health
Celgene Corporation (NASDAQ: CELG) and the Multiple Sclerosis
Association of America (MSAA) today announced the launch of a new
campaign, MS MindShift: A New View of MS, a national initiative
that provides new perspective on multiple sclerosis (MS). The campaign
aims to educate about the critical role the brain plays in the disease
and what people living with MS can do to keep their brain as healthy as
possible, for as long as possible.
May 16, 2019 08:30 am ET
Celgene Receives European Commission Approvals for REVLIMID® (lenalidomide) and IMNOVID® (pomalidomide)-based Triplet Combination Regimens for Patients with Multiple Myeloma
Celgene Corporation (NASDAQ:CELG), today announced that the European
Commission (EC) has approved two new triplet regimens based on Celgene’s
proprietary IMiD treatments, REVLIMID (lenalidomide) and IMNOVID
(pomalidomide).
May 15, 2019 05:04 pm ET
Celgene to Highlight New and Updated Hematology and Oncology Clinical Data at Upcoming American Society of Clinical Oncology (ASCO) 2019 Annual Meeting
Celgene Corporation (NASDAQ: CELG) today announced that data from more
than 40 company-sponsored, global alliance and investigator-initiated
clinical studies evaluating Celgene’s investigational and approved
therapies will be presented at the American Society of Clinical Oncology
(ASCO) 2019 Annual Meeting, May 31-June 4, in Chicago.
May 13, 2019 07:30 am ET
Celgene Corporation Announces POMALYST® Granted Breakthrough Therapy Designation from FDA for HIV-Positive and Negative Kaposi Sarcoma
Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and
Drug Administration (FDA) has granted Breakthrough Therapy designation
to POMALYST® (pomalidomide) for the treatment of patients with human
immunodeficiency virus (HIV)-positive Kaposi sarcoma who have previously
received systemic chemotherapy, as well as patients with HIV‐negative
Kaposi’s sarcoma.
May 10, 2019 07:30 am ET
Lyfebulb and Celgene Announce Finalists for 2019 "Addressing Unmet Needs in MS: An Innovation Challenge"
NEW YORK, May 10, 2019 /PRNewswire/ -- Lyfebulb, a chronic disease-focused, patient-empowerment platform that connects patients with industry to support user-driven innovation, and Celgene Corporation (NASDAQ: CELG) announced the 10 finalists chosen for the Lyfebulb-Celgene 2019 "Addressing Unmet Needs in MS: An Innovation Challenge."
May 07, 2019 07:30 am ET
Analysis Showed Oral Ozanimod Reduced Brain Volume Loss Across All Age Subgroups in Adults with Relapsing Multiple Sclerosis
Celgene Corporation (NASDAQ:CELG) today announced the results of a
post-hoc analysis of data from the Phase 3 RADIANCE™ Part B trial
showing that ozanimod reduced cortical grey matter volume loss versus
first-line treatment, Avonex® (interferon beta-1a), in adults
with relapsing multiple sclerosis (RMS) across all age groups, including
patients ages 18 to 25. The analysis will be presented at the 2019
American Academy of Neurology (AAN) Annual Meeting in Philadelphia, May
4-10, 2019.
May 01, 2019 05:01 pm ET
Celgene Corporation and bluebird bio Announce Results from Ongoing Multicenter Phase 1 Study of bb2121 anti-BCMA CAR T Cell Therapy in Patients with Multiple Myeloma Published in New England Journal o
Celgene Corporation (Nasdaq: CELG) and bluebird bio, Inc. (Nasdaq: BLUE)
today announced that the New England Journal of Medicine (NEJM)
has published interim results from CRB-401, the ongoing phase 1 study of
bb2121, the companies’ lead investigational BCMA-targeted chimeric
antigen receptor (CAR) T-cell therapy candidate for patients with
relapsed and refractory multiple myeloma.
Apr 26, 2019 07:30 am ET
Celgene Corporation and Acceleron Pharma Announce Submission of Luspatercept Marketing Authorization Application to the European Medicines Agency (EMA) for MDS and Beta-Thalassemia
Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ:
XLRN) today announced that Celgene has submitted a Marketing
Authorization Application (MAA) to the European Medicines Agency (EMA)
for luspatercept for the treatment of adult patients with very low to
intermediate-risk myelodysplastic syndromes (MDS)-associated anemia who
have ring sideroblasts, require red blood cell (RBC) transfusions
and have received or are not eligible for erythropoiesis-stimulating
agents, and for the treatment of adult patients with
beta-thalass
Apr 25, 2019 04:30 pm ET
Celgene Reports First Quarter 2019 Operating and Financial Results
Celgene Corporation (NASDAQ:CELG) reported net product sales of $4,024
million for the first quarter of 2019, a 14 percent increase from the
same period in 2018. Celgene reported first quarter 2019 total revenue
of $4,025 million, a 14 percent increase compared to $3,538 million in
the first quarter of 2018.
Apr 17, 2019 08:18 am ET
Bristol-Myers Squibb Company Announces Commencement of Exchange Offers and Consent Solicitations for Celgene Notes
Bristol-Myers Squibb Company (NYSE:BMY) (“Bristol-Myers Squibb)
announced today the commencement, in connection with its previously
announced acquisition of Celgene Corporation (NASDAQ:CELG) (“Celgene”),
of an exchange offer for any and all outstanding notes (the “Celgene
Notes”) issued by Celgene for up to $19,850,000,000 aggregate principal
amount of new notes to be issued by Bristol-Myers Squibb (the
“Bristol-Myers Squibb Notes”) and cash.
Apr 12, 2019 10:33 am ET
Celgene Stockholders Approve Proposed Acquisition by Bristol-Myers Squibb
Celgene Corporation (NASDAQ: CELG) today announced that its stockholders
have voted to approve the company’s proposed combination with
Bristol-Myers Squibb Company (NYSE: BMY). Approximately 98% of the votes
cast, and over 70% of the shares outstanding and entitled to vote, voted
in favor of the transaction at the special meeting.
Apr 05, 2019 09:28 am ET
Celgene Corporation and Acceleron Pharma Announce Submission of Luspatercept Biologics License Application to U.S. FDA
Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ:
XLRN) today announced that Celgene has submitted a Biologics License
Application (BLA) for luspatercept, an erythroid maturation agent, for
the treatment of adult patients with very low to intermediate risk
myelodysplastic syndromes (MDS)-associated anemia who have ring
sideroblasts and require red blood cell (RBC) transfusions and for the
treatment of adult patients with beta-thalassemia-associated anemia who
require RBC transfusions.
Apr 04, 2019 05:15 am ET
Report: Developing Opportunities within Mattel, Achillion Pharmaceuticals, Celgene, Adesto Technologies, New Residential Investment, and Entegris — Future Expectations, Projections Moving into 2019
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Mattel, Inc. (NASDAQ:MAT), Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN),...
Apr 01, 2019 09:31 am ET
Option-trading opportunities on Bank of America Corp., BlackBerry Ltd., Citigroup Inc., Celgene Corp., and The Walt Disney Co.
NEW YORK, April 1, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BAC, BB, C, CELG, and DIS.
Mar 29, 2019 12:00 pm ET
Celgene Settles U.S. REVLIMID® Patent Litigation with Alvogen
Celgene Corporation (NASDAQ:CELG) and Lotus Pharmaceutical Co., Ltd. and
Alvogen Pine Brook, LLC (collectively, Alvogen) today announced the
settlement of their litigation relating to patents for REVLIMID®
(lenalidomide).
Mar 29, 2019 09:31 am ET
Option-trading opportunities on BB&T Corp., Celgene Corp., Canada Goose Inc., Kroger Co., and PepsiCo Inc.
NEW YORK, March 29, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BBT, CELG, GOOS, KR, and PEP.
Mar 29, 2019 08:12 am ET
Celgene Receives CHMP Positive Opinions for Both REVLIMID® (lenalidomide) and IMNOVID® (pomalidomide)-Based Triplet Combination Regimens for Patients with Multiple Myeloma
Celgene Corporation (NASDAQ:CELG), today announced that the European
Medicines Agency's (EMA) Committee for Medicinal Products for Human Use
(CHMP) has adopted positive opinions for two triplet regimens based on
Celgene’s proprietary IMiD® medications, REVLIMID
(lenalidomide) and IMNOVID (pomalidomide).
Mar 25, 2019 04:30 pm ET
Celgene Submits Application to FDA for Ozanimod for the Treatment of Relapsing Forms of Multiple Sclerosis
Celgene Corporation (NASDAQ:CELG) today announced that the Company has
submitted a New Drug Application to the U.S. Food and Drug
Administration (FDA) for ozanimod for the treatment of adults with
relapsing forms of multiple sclerosis (RMS). Ozanimod is an oral,
sphingosine 1-phosphate (S1P) receptor modulator, which binds with high
affinity selectively to S1P subtypes 1 (S1P1) and 5 (S1P5).
Mar 25, 2019 06:59 am ET
Bristol-Myers Squibb Board of Directors Sends Letter to Shareholders Highlighting the Compelling Strategic and Financial Rationale of the Celgene Transaction; Company Provides Additional Investor Mate
Bristol-Myers Squibb Company’s (NYSE:BMY) Board of Directors today sent
an open letter to the Company’s shareholders regarding the previously
announced definitive merger agreement with Celgene Corporation
(NASDAQ:CELG). In addition to its March 19 investor presentation, the
Company today also made available on Bristol-Myers Squibb’s website at
Mar 12, 2019 04:30 pm ET
Celgene Provides Update on ABRAXANE® Combination Therapy in the Treatment of Metastatic Triple-Negative Breast Cancer and Pancreatic Cancer
Celgene Corporation (NASDAQ: CELG) today announced two updates for
ABRAXANE® (paclitaxel protein-bound particles for injectable
suspension) (albumin-bound) in the treatment of metastatic
triple-negative breast cancer and early stage pancreatic cancer.
Mar 11, 2019 07:30 am ET
Celgene Submits Application to EMA for Ozanimod for the Treatment of Relapsing-Remitting Multiple Sclerosis
Celgene Corporation (NASDAQ:CELG) today announced that the Company has
submitted a Marketing Authorization Application to the European
Medicines Agency (EMA) for ozanimod for the treatment of adults with
relapsing-remitting multiple sclerosis (RRMS). Ozanimod is an oral,
sphingosine 1-phosphate (S1P) receptor modulator, which binds with high
affinity selectively to S1P subtypes 1 (S1P1) and 5 (S1P5).
Mar 05, 2019 07:30 am ET
U.S. FDA Grants Priority Review for Fedratinib New Drug Application in Myelofibrosis
Celgene Corporation (NASDAQ:CELG) today announced the U.S. Food and Drug
Administration (FDA) has accepted the company’s New Drug Application
(NDA) for fedratinib and granted a Priority Review. Fedratinib is a
highly selective JAK2 inhibitor intended for the treatment of patients
with myelofibrosis, a serious bone marrow disorder that disrupts the
body’s normal production of blood cells.1 Under the
Prescription Drug User Fee Act, the FDA has set its action date as Sept.
3, 2019.
Feb 27, 2019 07:00 am ET
New Research Coverage Highlights Cisco, Mattel, Celgene, Vanda Pharmaceuticals, NuStar Energy, and Aon plc — Consolidated Revenues, Company Growth, and Expectations for 2019
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cisco Systems, Inc. (NASDAQ:CSCO), Mattel, Inc. (NASDAQ:MAT), Celgene...
Feb 26, 2019 07:30 am ET
Celgene Corporation Announces Key Regulatory Updates for REVLIMID® in Lymphoma and Luspatercept in MDS and Beta-Thalassemia
Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and
Drug Administration (FDA) has granted Priority Review designation for
the company’s supplemental New Drug Application (sNDA) for REVLIMID®
(lenalidomide) in combination with rituximab (R²) for the treatment of
patients with previously treated follicular and marginal zone lymphoma.
Under the Prescription Drug User Fee Act (PDUFA), the FDA has set its
action date as June 27, 2019.
Feb 25, 2019 11:55 pm ET
Gainey McKenna & Egleston Announces that It Filed a Class Action Lawsuit Against Celgene Corporation (CELG) And Its Directors
Gainey McKenna & Egleston announces that it filed a class action lawsuit against Celgene Corporation (“Celgene” or the “Company”) (Nasdaq: CELG) and its board of directors (the “Board”), on behalf of a proposed class consisting of all public...
Feb 14, 2019 12:57 pm ET
Feb 11, 2019 05:48 pm ET
CELGENE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Celgene Corporation - CELG
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the
law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the
proposed sale of Celgene Corporation (“Celgene”) (NasdaqGS: CELG) to
Bristol-Myers Squibb Company (“Bristol-Myers”) (NYSE: BMY). Under the
terms of the proposed transaction, shareholders of Celgene will receive
only $50.00 in cash and 1.0 shares of Bristol-Myers for each share of
Celgene that they own. KSF is seeking to determine whether this
consideration and the process that led to it are adequate, or whether
Feb 05, 2019 06:58 am ET
Lyfebulb and Celgene Announce Call for Innovation Challenge Applications to Address Unmet Needs in Multiple Sclerosis
NEW YORK, Feb. 5, 2019 /PRNewswire/ -- Lyfebulb, a chronic disease-focused, patient-empowerment platform that connects patients with industry and investors to support user-driven innovation, and Celgene Corporation (NASDAQ: CELG) announced the Lyfebulb-Celgene 2019 "Addressing Unmet Needs in MS: An Innovation Challenge" is now accepting applications. The goal of the initiative is to seek new solutions, beyond therapy, to help address either challenges faced by people with multiple sclerosis (MS) in their daily lives or an unmet need that could potentially improve outcomes and experiences for
Jan 31, 2019 07:30 am ET
Celgene Reports Fourth Quarter and Full Year 2018 Operating and Financial Results
Celgene Corporation (NASDAQ: CELG) reported operating results for the
fourth quarter and full year of 2018. For the fourth quarter of 2018,
net product sales were $4,036 million, an increase of 16 percent
year-over-year. Fourth quarter total revenue increased 16 percent
year-over-year to $4,037 million.
Jan 13, 2019 06:55 pm ET
INVESTOR ALERT: Monteverde & Associates PC is Investigating the Recently Announced Merger
NEW YORK, Jan. 13, 2019 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating:
Jan 08, 2019 10:15 am ET
CELGENE INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Celgene Corporation - CELG
NEW ORLEANS, Jan. 8, 2019 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Celgene Corporation ("Celgene") (NasdaqGS: CELG) to Bristol-Myers Squibb Company ("Bristol-Myers") (NYSE: BMY). Under the terms of the proposed transaction, shareholders of Celgene will receive only $50.00 in cash and 1.0 shares of Bristol-Myers for each share of Celgene that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether
Jan 07, 2019 07:30 am ET
Celgene Corporation Announces 2019 Financial Guidance and Key Milestones
Celgene Corporation (NASDAQ: CELG) today provides a business update,
including confirmation that the company achieved its guidance for
full-year 2018; its financial guidance for 2019; and reaffirmation of
its expected 2020 financial targets.
Jan 04, 2019 01:46 pm ET
CELGENE CORPORATION SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Merger
Rigrodsky & Long, P.A.:
Jan 04, 2019 11:32 am ET
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Celgene Corporation to Bristol-Myers Squibb Company is Fair to Shareholders
The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Celgene Corporation (“Celgene” or the “Company”) (NASDAQGS: CELG) stock prior to January 3, 2019. You are hereby notified that Levi &...
Jan 03, 2019 08:35 am ET
Celgene (CELG) Alert: Johnson Fistel Investigates Proposed Sale of Celgene Corporation; Are Celgene Shareholders Getting a Fair Deal?
SAN DIEGO, Jan. 3, 2019 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Celgene Corporation (NASDAQ: CELG) ("Celgene") breached their fiduciary duties in connection with the proposed sale of the Company to Bristol-Myers Squibb Company (NYSE: BMY) ("Bristol-Myers").
Jan 03, 2019 06:58 am ET
Bristol-Myers Squibb to Acquire Celgene to Create a Premier Innovative Biopharma Company
Bristol-Myers Squibb Company (NYSE:BMY) and Celgene Corporation
(NASDAQ:CELG) today announced that they have entered into a definitive
merger agreement under which Bristol-Myers Squibb will acquire Celgene
in a cash and stock transaction with an equity value of approximately
$74 billion. Under the terms of the agreement, Celgene shareholders will
receive 1.0 Bristol-Myers Squibb share and $50.00 in cash for each share
of Celgene. Celgene shareholders will also receive one tradeable
Contingent Value Right (CVR) for each share of Celgene, which wi
Dec 18, 2018 08:35 am ET
Celgene Corporation to Present at the 37th Annual J.P. Morgan Healthcare Conference
Celgene Corporation (NASDAQ:CELG) will present a business update and
provide 2019 financial guidance at the 37th Annual J.P.
Morgan Healthcare Conference on January 7, 2019 at 7:30 a.m. PT/ 10:30
a.m. ET. The presentation and breakout session can be accessed live by
webcast and will be made available in the Investor Relations section of
the Company’s website at
Dec 17, 2018 07:30 am ET
Celgene Corporation Announces Celgene Cancer Care Links™ Program Grant Recipients
Celgene Corporation (NASDAQ:CELG) today announced ten programs selected
for funding under its Celgene Cancer Care Links™ program, an initiative
designed to support cancer healthcare capacity building in
resource-constrained countries around the world.
Dec 10, 2018 07:20 am ET
Report: Developing Opportunities within Avangrid, GoDaddy, NGL Energy Partners LP, Lazard, Briggs & Stratton, and Celgene — Future Expectations, Projections Moving into 2019
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Avangrid, Inc. (NYSE:AGR), GoDaddy Inc. (NYSE:GDDY), NGL Energy Partners...
Dec 03, 2018 07:30 pm ET
Celgene Corporation Announces Initial Clinical Data from Ongoing Phase 1/2 Evolve Trial with Anti-BCMA CAR T Therapy JCARH125 in Relapsed/Refractory Multiple Myeloma at ASH 2018
Celgene Corporation (NASDAQ:CELG) today announced initial safety data
from its ongoing proof-of-concept trial of JCARH125 in patients with
relapsed/refractory multiple myeloma. JCARH125 is an investigational
BCMA-targeting CAR T cell therapy being developed by Juno Therapeutics,
A Celgene Company. Results were presented by Sham Mailankody, MBBS, in
an oral presentation at the 60th American Society of
Hematology (ASH) Annual Meeting and Exposition in San Diego, CA
(Abstract #957).
Dec 02, 2018 07:35 pm ET
Celgene Corporation Announces Results of AUGMENT Evaluating REVLIMID® In Combination with Rituximab (R2) In Patients with Relapsed/Refractory Indolent Lymphoma At ASH 2018
Celgene Corporation (NASDAQ: CELG) today announced results of the phase
3 AUGMENT study, which showed that REVLIMID® (lenalidomide)
in combination with rituximab (R2) demonstrated superior
progression-free survival (PFS) in patients with relapsed/refractory
indolent lymphoma compared to patients who received rituximab plus
placebo (R-placebo). The data were presented by John Leonard, M.D. in an
oral presentation at the 60th American Society of Hematology
(ASH) Annual Meeting and Exposition in San Diego, C.A. (Abs
Dec 02, 2018 07:30 pm ET
bluebird bio and Celgene Corporation Present Initial Data from Ongoing Phase 1 Clinical Study of Next-Generation Anti-BCMA CAR T Cell Therapy bb21217 in Patients with Relapsed/Refractory Multiple Myel
bluebird
bio, Inc. (Nasdaq:BLUE) and Celgene Corporation (NASDAQ:CELG)
announced initial data from the ongoing Phase 1 clinical study of
bb21217 (CRB-402), an investigational next-generation anti-BCMA CAR T
cell therapy being studied in patients with relapsed/refractory multiple
myeloma. The data were presented by Nina Sh
Dec 02, 2018 05:00 pm ET
Celgene Corporation and Acceleron Pharma Announce Results of the Phase 3 MEDALIST Trial Evaluating Luspatercept in Patients with Myelodysplastic Syndromes at the ASH 2018 Plenary Session
Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ:
XLRN) today announced results from the pivotal, phase 3 MEDALIST trial
evaluating the efficacy and safety of investigational luspatercept to
treat patients with ring sideroblast (RS+) myelodysplastic syndromes
(MDS)-associated anemia who require red blood cell transfusions and who
had failed, were intolerant to, or ineligible for erythropoietin
therapy. Results were presented by Alan F. List, M.D. during the Plenary
Scientific Session at the 60th American Society of
Dec 02, 2018 10:35 am ET
Celgene Corporation Announces Initial Phase 1/2 Liso-cel Data in Patients with Relapsed/Refractory CLL, Including Those with High-Risk Disease, Previously Treated with Ibrutinib, at ASH 2018
Celgene Corporation (NASDAQ: CELG) today announced initial data from the
dose-escalation part of an ongoing, open-label multicenter phase 1/2
study of investigational lisocabtagene maraleucel (liso-cel; JCAR017) in
patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and
small lymphocytic lymphoma (SLL), including patients with cytogenetic
features of high-risk disease, who were previously treated with
ibrutinib. The data were presented by Tanya Siddiqi, M.D. in an oral
presentation at the 60th American Society of Hema
Dec 01, 2018 05:00 pm ET
Celgene Corporation and Acceleron Pharma Announce Results of the Phase 3 BELIEVE Trial Evaluating Luspatercept in Adult Patients with Beta-Thalassemia at ASH 2018
Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ:
XLRN) today announced results from a pivotal, phase 3 trial (BELIEVE)
evaluating the safety and efficacy of luspatercept for the treatment of
adults with beta-thalassemia-associated anemia who require regular red
blood cell (RBC) transfusions. The data were presented by Maria Domenica
Cappellini, M.D. in an oral session of the 60th American
Society of Hematology (ASH) Annual Meeting and Exposition in San Diego,
CA (Abstract #163).
Nov 27, 2018 07:30 am ET
Celgene Corporation and bluebird bio Complete Enrollment of Pivotal KarMMa Study of anti-BCMA Car T Cell Therapy bb2121 in Patients with Relapsed and Refractory Multiple Myeloma
Celgene Corporation (Nasdaq: CELG) and bluebird bio, Inc. (Nasdaq: BLUE)
today announced the completion of enrollment for the KarMMa pivotal
study of bb2121, the companies’ lead investigational anti-BCMA CAR T
cell therapy candidate for patients with relapsed and refractory
multiple myeloma. bb2121 is being developed as part of a Co-Development,
Co-Promote and Profit Share Agreement between Celgene and bluebird bio.
Nov 14, 2018 06:58 am ET
Lyfebulb Partners with Celgene to Inspire Patient-Driven Innovation in the Management of Multiple Sclerosis
NEW YORK, Nov. 14, 2018 /PRNewswire/ -- Lyfebulb, a chronic disease-focused, patient-empowerment platform that connects patients with industry and investors to support user-driven innovation, announced it is joining forces with Celgene (NASDAQ: CELG) to launch Addressing Unmet Needs in MS: An Innovation Challenge, to seek new solutions aimed at addressing the daily challenges associated with multiple sclerosis (MS).
Nov 02, 2018 07:30 am ET
Celgene Corporation to Webcast at Upcoming Investor Events
Celgene Corporation (NASDAQ:CELG) plans to present at two upcoming
investor events where Celgene management will provide an overview of the
Company. The events will be webcast live and will be available in the
Investor Relations section of the Company’s website at www.celgene.com.
Nov 01, 2018 09:50 am ET
Results from More Than 100 Abstracts Highlighting Celgene Pipeline Compounds and Therapies to Be Presented at the American Society of Hematology Annual Meeting (ASH)
Celgene Corporation (NASDAQ:CELG) today announced that data from more
than 100 abstracts, including a study being featured as a plenary
presentation and more than 40 selected for oral presentations,
evaluating Celgene investigational agents and investigational uses of
marketed products will be presented at the 60th American
Society of Hematology Annual Meeting between Dec. 1-4 in San Diego, CA.
Oct 31, 2018 08:00 am ET
New Research: Key Drivers of Growth for Celgene, Briggs & Stratton, NewJersey Resources, RPM International, Anixter International, and Sensient Technologies — Factors of Influence, Major Initiatives a
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Celgene Corporation (NASDAQ:CELG), Briggs & Stratton Corporation...
Oct 25, 2018 07:30 am ET
Celgene Reports Third Quarter 2018 Operating and Financial Results
Celgene Corporation (NASDAQ:CELG) reported net product sales of $3,890
million for the third quarter of 2018, an 18 percent increase from the
same period in 2017. Celgene reported third quarter 2018 total revenue
of $3,892 million, an 18 percent increase compared to $3,287 million in
the third quarter of 2017.
Oct 24, 2018 09:13 am ET
TV Host and Fashion Journalist Louise Roe Shares Her Personal Story With Plaque Psoriasis as Part of INSIDE PERSPECTIVE Campaign
TV host and fashion journalist Louise Roe launches the INSIDE
PERSPECTIVE campaign with Celgene Corporation (NASDAQ: CELG) and Otezla®
(apremilast), and for the first time, shares her inside story with
psoriasis, a condition she has been living with for more than a decade.
Louise knows that outward appearances can be deceiving, which is why
going beneath the surface can give you an entirely new perspective. As
part of the campaign, she hopes to raise awareness about psoriasis,
which appears on the surface of the skin but actually star
Oct 23, 2018 04:30 pm ET
REVLIMID® (lenalidomide) Demonstrated a Significant Improvement in Progression-Free Survival (PFS) Compared with Observation in a Randomized Study in Patients with Smoldering Multiple Myeloma
Celgene Corporation (NASDAQ: CELG) today announced results from an
open-label phase II/III National Clinical Trials Network (NCTN) study
led by the ECOG-ACRIN Cancer Research Group and sponsored by the
National Cancer Institute (NCI), part of the National Institutes of
Health. REVLIMID® (lenalidomide) was provided by
Celgene under a clinical trials agreement with the NCI’s Division of
Cancer Treatment and Diagnosis.
Oct 22, 2018 04:30 pm ET
Celgene Corporation Announces Appointment of Dr. Alise Reicin to President, Global Clinical Development
Celgene Corporation (NASDAQ:CELG) today announced the appointment of Dr.
Alise Reicin to President, Global Clinical Development, reporting to
Mark J. Alles, Chairman and Chief Executive Officer, effective November
1, 2018. In this role, Dr. Reicin will be responsible for all aspects of
mid- to late-stage clinical development across Celgene’s portfolio and
will serve on the company's Executive Committee.
Oct 22, 2018 07:30 am ET
First Results of New Data of ABRAXANE in Combination with Atezolizumab Presented at ESMO 2018
Celgene Corporation (NASDAQ:CELG) today announced the first results from
the IMpassion130 study evaluating ABRAXANE® (paclitaxel
protein-bound particles for injectable suspension) (albumin-bound) in
combination with atezolizumab (Tecentriq®) in patients with
first-line locally advanced triple negative breast cancer (TNBC) and the
IMpower130 study evaluating ABRAXANE/carboplatin in combination with
atezolizumab in first-line advanced non-squamous non-small cell lung
cancer. These findings were presented at the European Socie
Oct 11, 2018 07:30 am ET
Survey Results Presented at ECTRIMS Reveal People with Multiple Sclerosis Want More Information on Brain Atrophy
A new survey examines the topic of brain volume loss, known as brain
atrophy, in people with multiple sclerosis. The survey findings,
presented at ECTRIMS 2018, suggest that there is a high level of
interest in better understanding how brain atrophy may impact disease
progression. Sixty-three percent of respondents reported that they have
not talked to any member of their medical team about brain atrophy; only
20 percent reported being moderately or very satisfied with the amount
of information available on potential ways to prevent brain atroph
Oct 10, 2018 07:30 am ET
New Analyses from Pivotal Phase 3 Trials of Oral Ozanimod to Be Presented at ECTRIMS 2018
Celgene Corporation (NASDAQ:CELG) today announced the results of two
post hoc analyses of data from the phase 3 SUNBEAM™ and RADIANCE™ Part B
trials, which evaluated the efficacy and safety of ozanimod, a novel,
oral, selective sphingosine 1-phosphate 1 (S1P1) and 5 (S1P5)
receptor modulator, versus a first-line treatment, Avonex®
(interferon beta-1a) (IFN), in patients with relapsing multiple
sclerosis (RMS). These findings will be presented at ECTRIMS 2018.
Oct 08, 2018 04:37 pm ET
Celgene Announces Phase 3 STYLE Study of OTEZLA® (apremilast) in Moderate to Severe Scalp Psoriasis Met Primary Endpoint
Celgene Corporation (NASDAQ:CELG) today announced results from the phase
3 STYLE study, which showed that OTEZLA® (apremilast) 30 mg
twice daily achieved a highly statistically significant improvement in
the primary endpoint of the Scalp Physician’s Global Assessment (ScPGA)
response [defined as ScPGA score of clear (0) or almost clear (1) with
at least a 2-point reduction from baseline] at week 16 compared with
placebo.
Oct 01, 2018 07:30 am ET
Celgene Corporation to Announce Third Quarter 2018 Results on October 25, 2018
Celgene Corporation (NASDAQ:CELG) will host a conference call and live
audio webcast on Thursday, October 25, 2018 at 9 a.m. ET to discuss
third quarter 2018 financial and operational results. The webcast can be
accessed from the Investor Relations page at www.celgene.com.
Sep 27, 2018 08:25 am ET
Report: Exploring Fundamental Drivers Behind Ryanair, Ctrip.com International, CyrusOne, Fabrinet, Celgene, and AT&T — New Horizons, Emerging Trends, and Upcoming Developments
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ryanair Holdings PLC (NASDAQ:RYAAY), Ctrip.com International, Ltd....
Sep 24, 2018 10:01 am ET
S&P 500 Q2 2018 Buybacks Increase 58.7% Year-Over-Year to Record $190.6 Billion
NEW YORK, Sept. 24, 2018 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") today announced preliminary results indicating that S&P 500® stock buybacks, or share repurchases, totaled $190.6 billion for Q2 2018, displacing the prior quarterly record of $189.1 billion, set during Q1 2018. This is a 58.7% increase from the $120.1 billion reported for Q2 2017. For the first half of 2018, buybacks are up 49.9% to $379.7 billion from the prior year's $253.3 billion.
Sep 12, 2018 07:30 am ET
OTEZLA® (Apremilast) Showed Meaningful Improvements in Clinical and Quality-of-Life Measures of Psoriasis Beyond Those Captured by Assessing Skin Alone
Celgene Corporation (NASDAQ:CELG) today announced the results of two
post hoc sub-analyses of clinical trials for OTEZLA®
(apremilast) at the 27th European Academy of Dermatology and
Venereology (EADV) Congress in Paris, France. Findings suggest OTEZLA
offered meaningful improvements in outcomes important to patients with
moderate to severe plaque psoriasis, which may not be captured by common
measures of treatment efficacy that focus only on skin clearance, such
as Psoriasis Area Severity Index (PASI) 75.
Sep 11, 2018 09:31 am ET
Thinking about buying stock in American Tower, Alibaba, Celgene, Callaway Golf Co. or Marathon Petroleum Corp.?
NEW YORK, Sept. 11, 2018 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMT, BABA, CELG, ELY, and MPC.
Aug 23, 2018 07:30 am ET
Celgene Corporation to Webcast at Upcoming Investor Conferences
Celgene Corporation (NASDAQ: CELG) plans to present at two upcoming
investor conferences where Celgene management will provide an overview
of the Company. The events will be webcast live and will be available in
the Investor Relations section of the Company’s website at www.celgene.com.
Jul 26, 2018 07:30 am ET
Celgene Reports Second Quarter 2018 Operating and Financial Results
Celgene Corporation (NASDAQ:CELG) reported net product sales of $3,808
million for the second quarter of 2018, a 17 percent increase from the
same period in 2017. Celgene reported second quarter 2018 total revenue
of $3,814 million, a 17 percent increase compared to $3,271 million in
the second quarter of 2017.
Jul 23, 2018 04:30 pm ET
Celgene Announces Phase III ‘AUGMENT’ Study of REVLIMID® in Combination with Rituximab (R2) for the Treatment of Patients with Relapsed/Refractory Indolent Lymphoma Met Primary Endpoint
Celgene Corporation (NASDAQ: CELG) today announced results from a phase
III, randomized, double-blind, international clinical study (AUGMENT).
REVLIMID® (lenalidomide) plus rituximab (R2)
achieved a highly statistically significant improvement in the primary
endpoint of progression-free survival (PFS), compared to rituximab plus
placebo, in the final PFS analysis.
Jul 10, 2018 07:30 am ET
Anti-PD-L1 Immunotherapy Plus ABRAXANE® Significantly Reduced the Risk of Disease Worsening or Death in Patients with Metastatic or Locally Advanced Triple Negative Breast Cancer in Phase III IMpassio
Celgene Corporation (NASDAQ:CELG) today announced that the Phase III
IMpassion130 study, which was sponsored by Roche, met its co-primary
endpoint of progression-free survival (PFS). This is the first phase III
study to demonstrate a statistically significant PFS improvement in
first-line metastatic or unresectable locally advanced triple negative
breast cancer (TNBC), a type of breast cancer with high unmet need.
Jul 09, 2018 04:52 pm ET
Celgene and Acceleron Announce Luspatercept Achieved Primary and All Key Secondary Endpoints in Phase III ‘BELIEVE’ Study in Adults with Transfusion-Dependent Beta-Thalassemia
Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ:
XLRN) today announced results from a phase III, randomized,
double-blind, multi-center clinical study (BELIEVE). Luspatercept
achieved a highly statistically significant improvement in the primary
endpoint of erythroid response, which was defined as at least a 33
percent reduction from baseline in red blood cell (RBC) transfusion
burden with a reduction of at least 2 units during the protocol-defined
period of 12 consecutive weeks, from week 13 to week 24, compared to
p
Jul 02, 2018 07:30 am ET
Celgene Corporation to Announce Second Quarter 2018 Results on July 26, 2018
Celgene Corporation (NASDAQ: CELG) will host a conference call and live
audio webcast on Thursday, July 26, 2018 at 9 a.m. ET to discuss second
quarter 2018 financial and operational results. The webcast can be
accessed from the Investor Relations page at www.celgene.com.
Jun 28, 2018 04:30 pm ET
Celgene and Acceleron Announce Luspatercept Achieved Primary and Key Secondary Endpoints in Phase III ‘MEDALIST’ Study in Patients with Low-to-Intermediate Risk Myelodysplastic Syndromes
Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ:
XLRN) today announced results from a phase III, randomized,
double-blind, multi-center clinical study (MEDALIST). Luspatercept
achieved a highly statistically significant improvement in the primary
endpoint of red blood cell (RBC) transfusion independence of at least 8
consecutive weeks during the first 24 weeks compared to placebo.
Jun 19, 2018 04:30 pm ET
Celgene Corporation Announces Appointment of Jonathan Biller as Executive Vice President and General Counsel Following the Departure of Gerald F. Masoudi
Celgene Corporation (NASDAQ:CELG) today announced the appointment of
Jonathan Biller as Executive Vice President and General Counsel
effective July 3, 2018. Mr. Biller will be responsible for global legal
strategy and will serve on the company's Executive Committee.
Jun 14, 2018 08:20 am ET
Report: Developing Opportunities within Equinix, Sonus Networks, Celgene, National Grid, Atlas Air Worldwide, and Copa Holdings, S.A. — Future Expectations, Projections Moving into 2018
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Equinix, Inc. (NASDAQ:EQIX), Sonus Networks, Inc. (NASDAQ:RBBN), Celgene...
Jun 03, 2018 12:09 pm ET
Celgene Announces Updated Safety and Efficacy Data from the TRANSCEND Trial of liso-cel (JCAR017) in Patients with Relapsed or Refractory B-cell non-Hodgkin Lymphoma at ASCO
Celgene Corporation (NASDAQ:CELG) today announced updated six-month
safety and efficacy data from the TRANSCEND (NHL-001) study of
lisocabtagene maraleucel (liso-cel; JCAR017), an investigational
CD19-directed CAR T cell therapy, in patients with relapsed/refractory
(r/r) aggressive B-cell non-Hodgkin lymphoma (NHL) in a presentation at
the American Society of Clinical Oncology (ASCO) Annual Meeting in
Chicago, IL.
Jun 03, 2018 10:45 am ET
Results of Phase III RELEVANCE Study Comparing REVLIMID plus Rituximab (R2) Versus Rituximab Plus Chemotherapy in Patients with Previously Untreated Follicular Lymphoma to be Presented at ASCO 2018
Celgene Corporation (NASDAQ:CELG) today announced additional results
from RELEVANCE, a phase III, randomized, open-label, international
clinical study conducted in partnership with the Lymphoma Academic
Research Organisation (LYSARC), were presented at the 54th
Annual American Society of Clinical Oncology Scientific Sessions (ASCO)
in Chicago, Illinois on June 1-5, 2018.
Jun 01, 2018 05:57 pm ET
Updated Results of Ongoing Multicenter Phase I Study of bb2121 anti-BCMA CAR T Cell Therapy Continue to Demonstrate Deep and Durable Responses in Patients with Late-Stage Relapsed/Refractory Multiple
Celgene Corporation (NASDAQ:CELG) and bluebird
bio, Inc. (NASDAQ:BLUE) today announced
updated results from the ongoing CRB-401 phase I clinical study of
bb2121, an investigational anti-B-cell maturation antigen (BCMA) CAR T
cell therapy, in 43 patients with late-stage relapsed/refractory
multiple
Jun 01, 2018 04:00 pm ET
Results of Phase III OPTIMISMM Study Presented at ASCO 2018 Showed the PVd Triplet Improved PFS in Early Lines of Relapsed or Refractory Multiple Myeloma
Celgene Corporation (NASDAQ:CELG) today announced results from the
OPTIMISMM study, a phase III, randomized, open-label, international
clinical study of the investigational combination regimen of POMALYST®
(pomalidomide), bortezomib and dexamethasone in patients with relapsed
or refractory multiple myeloma (RRMM) who had received at least one
prior treatment including lenalidomide. The results were presented at
the 54th Annual American Society of Clinical Oncology
Scientific Sessions (ASCO) in Chicago, Illinois on June 1-5,
May 31, 2018 04:30 pm ET
Celgene Corporation Announces Hiring of David V. Elkins as Executive Vice President, Chief Financial Officer and Appointment of Peter N. Kellogg to Executive Vice President, Chief Corporate Strategy O
Celgene Corporation (NASDAQ:CELG) today announced the hiring of David V.
Elkins as Executive Vice President (EVP), Chief Financial Officer (CFO).
Mr. Elkins will join Celgene on July 1, 2018, and become CFO effective
August 1, 2018. Mr. Elkins will succeed current CFO Peter N. Kellogg,
who will become Celgene’s EVP, Chief Corporate Strategy Officer until
his retirement, planned for mid-2019.
May 29, 2018 01:33 pm ET
The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Celgene Corporation (CELG)
Law Offices of Howard G. Smith reminds investors of the May 29,
2018 deadline to file a lead plaintiff motion in the class action
filed on behalf of investors that purchased Celgene Corporation
(“Celgene” or the “Company”) (NASDAQ: CELG)
securities between January 12, 2015 and February 27, 2018, inclusive
May 29, 2018 10:47 am ET
DEADLINE TODAY: The Klein Law Firm Reminds Investors of a Class Action Commenced on Behalf of Celgene Corporation Shareholders and a Lead Plaintiff Deadline of May 29, 2018 (CELG)
The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Celgene Corporation (NASDAQ:CELG) who purchased shares between January 12, 2015 and February 27, 2018. The action, which was filed in the United...
May 28, 2018 10:50 pm ET
CELGENE 24 HOUR DEADLINE ALERT: Approximately 24 Hours Remain; ClaimsFiler Reminds Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuit against Celgene Corporation - CELG
ClaimsFiler, a FREE shareholder information service, reminds investors
that they have only until May 29, 2018 to file lead plaintiff
applications in a securities class action lawsuit against Celgene
Corporation (NasdaqGS: CELG). Investor losses must relate to purchases
of the Company’s shares between January 12, 2015 and February 27, 2018.
This action is pending in the United States District Court for the
District of New Jersey.
May 25, 2018 10:50 pm ET
CELGENE 96 HOUR DEADLINE ALERT: Approximately 96 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors with Losses in Excess of $100,000 of Deadline in Class Acti
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney
General of Louisiana, Charles C. Foti, Jr., remind investors with large
financial interests that they have only until May 29, 2018 to
file lead plaintiff applications in a securities class action lawsuit
against Celgene Corporation (NasdaqGS: CELG). Investor losses must
relate to purchases of the Company’s shares between January 12, 2015 and
February 27, 2018. This action is pending in the United States District
Court for the District of New Jersey.
May 25, 2018 03:46 pm ET
CELGENE LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Celgene Corporation To Contact The Firm
NEW YORK, May 25, 2018 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Celgene Corporation ("Celgene" or the "Company") (NASDAQ: CELG) of the May 29, 2018 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
May 24, 2018 07:36 pm ET
$100,000 Threshold: Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Celgene Corporation Investors (CELG)
Glancy Prongay Murray LLP (“GPM”) announces that a class action lawsuit has been filed on behalf of investors that purchased or otherwise acquired the securities of Celgene Corporation (“Celgene” or the “Company”) (NASDAQ:CELG) between September...
May 24, 2018 07:30 am ET
Celgene Corporation Announces Additional $3 Billion Share Repurchase Authorization and Plans to Execute a $2 Billion Accelerated Share Repurchase Program
Celgene Corporation (NASDAQ: CELG) today announced that the Company's
Board of Directors authorized the repurchase of an additional $3 billion
of the Company's common stock. In addition, the Company plans to enter
into an accelerated share repurchase (ASR) agreement to repurchase an
aggregate of $2 billion of the Company’s common stock. The planned ASR
will utilize part of the existing Board authorized share repurchase
program as well as part of the new authorization.
May 23, 2018 03:00 pm ET
CELG EQUITY: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Celgene Corporation and a Lead Plaintiff Deadline of May 29, 2018
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Celgene Corporation ("Celgene") (NASDAQ:CELG) securities...
May 22, 2018 07:18 pm ET
The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Celgene Corporation (CELG)
Law Offices of Howard G. Smith reminds investors of the May 29,
2018 deadline to file a lead plaintiff motion in the class action
filed on behalf of investors that purchased Celgene Corporation
(“Celgene” or the “Company”) (NASDAQ: CELG)
securities between January 12, 2015 and February 27, 2018, inclusi
May 22, 2018 05:42 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Celgene Corporation To Contact The Firm
Faruqi Faruqi, LLP, a leading national securities law firm, reminds investors in Celgene Corporation (“Celgene” or the “Company”) (NASDAQ:CELG) of the May 29, 2018 deadline to seek the role of lead plaintiff in a federal securities class action...
May 22, 2018 11:59 am ET
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Celgene Corporation of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 29, 2018 – CELG
The following statement is being issued by Levi Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Celgene Corporation ("Celgene") (NASDAQ:CELG) between January 12, 2016 and February 27, 2018. You are...
May 22, 2018 08:00 am ET
FINAL DEADLINE ALERT: Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Celgene Corporati
STEVENSON, Md., May 22, 2018 (GLOBE NEWSWIRE) -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of...
May 21, 2018 09:30 pm ET
Deadline Alert: Glancy Prongay & Murray LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against Celgene Corporation (CELG)
Glancy
Prongay & Murray LLP (“GPM”) reminds investors of the May
29, 2018 deadline to file a lead plaintiff motion in the class
action filed on behalf of investors that purchased Celgene Corporation
(“Celgene” or the “Company”) (NASDAQ:
May 18, 2018 10:50 pm ET
CELGENE SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Celgene Corporation - CELG
ClaimsFiler, a FREE shareholder information service, reminds investors that they have until May 29, 2018 to file lead plaintiff applications in a securities class action lawsuit against Celgene Corporation (NasdaqGS:CELG), if they purchased the...
May 16, 2018 05:30 pm ET
Celgene to Present New Clinical Data in Blood Cancer and Solid Tumor Therapies at Upcoming American Society of Clinical Oncology (ASCO) Scientific Sessions
Celgene Corporation (NASDAQ: CELG) today announced that data from more
than 60 company-sponsored, cooperative group and investigator-initiated
clinical studies evaluating Celgene agents will be presented at the
American Society of Clinical Oncology Annual Meeting between June 1-5 in
Chicago, Ill.
May 16, 2018 10:07 am ET
Hagens Berman Reminds Investors in Celgene Corporation (CELG) of the May 29, 2018 Securities Class Action Lead Plaintiff Deadline
SAN FRANCISCO, May 16, 2018 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP reminds investors in Celgene Corporation (NASDAQ: CELG) of the May 29, 2018 securities class action Lead Plaintiff deadline. If you purchased or otherwise acquired Celgene securities between January 12, 2015 and February 27, 2018 and suffered losses contact Hagens Berman Sobol Shapiro LLP. For more information visit:
May 15, 2018 01:00 pm ET
Nohla Therapeutics Announces Closing of $45 Million Series B Financing
Nohla Therapeutics, a leading developer of universal, off-the-shelf cell therapies for patients with hematologic malignances and other critical diseases, today announced the closing of a $45 million Series B financing. In this round, Fidelity...
May 14, 2018 07:30 am ET
Celgene Corporation to Webcast at Upcoming Investor Conferences and Events
Celgene Corporation (NASDAQ: CELG) plans to present at four upcoming
investor conferences and events where Celgene management will provide an
overview of the Company. The events will be webcast live and will be
available in the Investor Relations section of the Company’s website at www.celgene.com.
May 11, 2018 10:50 pm ET
CELGENE SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Ce
Kahn Swick Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until May 29, 2018 to file lead plaintiff applications in a securities class action lawsuit against Celgene...
May 10, 2018 09:00 pm ET
Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Celgene Corporation Investors (CELG)
Glancy
Prongay & Murray LLP (“GPM”) announces that a class action
lawsuit has been filed on behalf of investors that purchased or
otherwise acquired the securities of Celgene Corporation (“Celgene” or
the “Company”) (NASDAQ:
May 09, 2018 03:17 pm ET
CLASS UPDATE: The Klein Law Firm Reminds Investors of a Class Action Commenced on Behalf of Celgene Corporation Shareholders and a Lead Plaintiff Deadline of May 29, 2018 (CELG)
The Klein Law Firm announces that a class action complaint has been
filed on behalf of shareholders of Celgene Corporation (NASDAQ: CELG)
who purchased shares between January 12, 2015
and February 27, 2018. The action, which
was filed in the United States District Court for the District of New
Jersey, alleges that the Company violated federal securities laws.
May 07, 2018 03:22 pm ET
CELG EXPANDED CLASS: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Celgene Corporation and a Lead Plaintiff Deadline of May 29, 2018
The Law Offices of Vincent Wong announce that a class action lawsuit has
been commenced in the United States District Court for the District of
New Jersey on behalf of investors who purchased Celgene Corporation
("Celgene") (NASDAQ:CELG) securities between January
12, 2015 and February 27, 2018.
May 04, 2018 10:50 pm ET
CELGENE SHAREHOLDER ALERT: ClaimsFiler Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit against Celgene Corporation - CELG
ClaimsFiler, a FREE shareholder information service, reminds investors
that they have until May 29, 2018 to file lead plaintiff
applications in a securities class action lawsuit against Celgene
Corporation (NasdaqGS: CELG), if they purchased the Company’s shares
between January 12, 2015 and February 27, 2018, inclusive (the “Class
Period”). This action is pending in the United States District Court for
the District of New Jersey.
May 04, 2018 05:53 pm ET
Hagens Berman Alerts Investors in Celgene Corporation to the Expanded Class Period and Reminds Them of the May 29, 2018 Securities Class Action Lead Plaintiff Deadline
Hagens Berman Sobol Shapiro LLP reminds investors in Celgene Corporation (NASDAQ:CELG) of the May 29, 2018 Lead Plaintiff deadline. If you purchased or otherwise acquired Celgene securities during the expanded class period – between January 12,...
May 04, 2018 03:00 pm ET
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Celgene Corporation of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 29, 2018
The following statement is being issued by Levi & Korsinsky, LLP:
May 04, 2018 07:30 am ET
Celgene Reports First Quarter 2018 Operating and Financial Results
Celgene Corporation (NASDAQ:CELG) reported net product sales of $3,531
million for the first quarter of 2018, a 20 percent increase from the
same period in 2017. Celgene reported first quarter 2018 total revenue
of $3,538 million, a 19 percent increase compared to $2,962 million in
the first quarter of 2017.
May 03, 2018 06:34 pm ET
Kessler Topaz Meltzer & Check, LLP Announces Expanded Class Period in Securities Class Action Filed against Celgene Corporation
The law firm of Kessler Topaz Meltzer & Check, LLP announces that it has
filed an expanded securities fraud class action complaint against
Celgene Corporation (Nasdaq: CELG) (“Celgene” or the “Company”) on
behalf of investors who purchased the Company’s securities between
January 12, 2015 and February 27, 2018, inclusive (the “Class Period”).
This action, captioned Witchcoff v. Celgene Corp., et al., Case
No. 18-08785 was filed in the United States District Court for the
District of New Jersey and is related to a previously filed a
May 02, 2018 11:51 am ET
The Klein Law Firm Announces a Class Action Commenced on Behalf of Celgene Corporation Shareholders and a Lead Plaintiff Deadline of May 29, 2018 (CELG)
The Klein Law Firm announces that a class action complaint has been
filed on behalf of shareholders of Celgene Corporation (NASDAQ: CELG)
who purchased shares between September 12, 2016
and February 27, 2018. The action, which
was filed in the United States District Court for the District of New
Jersey, alleges that the Company violated federal securities laws.
May 02, 2018 10:00 am ET
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Celgene Corporation (CELG) and Lead Plaintiff Deadline - May 29, 2018
NEW YORK, May 02, 2018 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed Celgene Corporation (“Celgene” or the “Company”) (NASDAQ:CELG) and certain of its officers, on behalf of shareholders who...
May 02, 2018 08:00 am ET
DEADLINE ALERT: Brower Piven Reminds Investors of Upcoming Deadline in Class Action Lawsuit and Encourages Those Who Have Losses in Excess of $100,000 from Investment in Celgene Corporation to Contact
The securities litigation law firm of Brower Piven, A Professional
Corporation, announces that a class action lawsuit has been commenced in
the United States District Court for the District of New Jersey on
behalf of purchasers of Celgene Corporation (Nasdaq: CELG) (“Celgene” or
the “Company”) securities during the period between September 12, 2016
and February 27, 2018, inclusive (the “Class Period”). Investors who
wish to become proactively involved in the litigation have until May 29,
2018 to seek appointment as lead plaintiff.
Apr 30, 2018 03:48 pm ET
The Klein Law Firm Announces a Class Action Filed on Behalf of Celgene Corporation Shareholders and a Lead Plaintiff Deadline of May 29, 2018 (CELG)
NEW YORK, April 30, 2018 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Celgene Corporation (NASDAQ:CELG) who purchased shares between September 12, 2016 and February...
Apr 30, 2018 07:30 am ET
Celgene Corporation Announces Appointment of Jennifer Dudinak to Senior Vice President of Global Regulatory Affairs
Celgene Corporation (NASDAQ:CELG) today announced the appointment of
Jennifer Dudinak, Pharm.D., as Senior Vice President, Global Regulatory
Affairs, reporting to Jay Backstrom, M.D., Chief Medical Officer,
effective April 30, 2018. Jennifer will be responsible for regulatory
strategy and execution across Celgene’s portfolio and will serve on the
company's Executive Committee.
Apr 27, 2018 10:50 pm ET
CELGENE SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Celgene Corporation - CELG
NEW ORLEANS, April 27, 2018 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until May 29, 2018 to file lead plaintiff applications in a securities class action lawsuit against Celgene Corporation (NasdaqGS: CELG), if they purchased the Company's shares between September 12, 2016 and February 27, 2018, inclusive (the "Class Period"). This action is pending in the United States District Court for the District of New Jersey.
Apr 27, 2018 03:37 pm ET
CELG INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Celgene Corporation and a Lead Plaintiff Deadline of May 29, 2018
The Law Offices of Vincent Wong announce that a class action lawsuit has
been commenced in the United States District Court for the District of
New Jersey on behalf of investors who purchased Celgene Corporation
("Celgene") (NASDAQ: CELG) securities between September
12, 2016 and February 27, 2018.
Apr 24, 2018 07:30 am ET
New Analyses from Pivotal Phase III Trials of Oral Ozanimod in Relapsing Multiple Sclerosis To Be Presented at the 2018 American Academy of Neurology Annual Meeting
Celgene Corporation (NASDAQ:CELG) today announced additional phase III
data analyses evaluating the efficacy and safety of ozanimod, a novel,
oral, selective sphingosine 1-phosphate 1 (S1P1) and 5 (S1P5)
receptor modulator, versus interferon beta-1a (IFN β-1a) (Avonex®)
in patients with relapsing multiple sclerosis (RMS). These additional
data analyses from the SUNBEAM™ and RADIANCE™ Part B trials are being
presented at the 2018 American Academy of Neurology (AAN) Annual Meeting
in Los Angeles, April 21-27, 2018.
Apr 23, 2018 05:00 pm ET
CELG SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving Celgene Corporation and a Lead Plaintiff Deadline of May 29, 2018
NEW YORK, April 23, 2018 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of...
Apr 20, 2018 10:50 pm ET
CELGENE SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Ce
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General
of Louisiana, Charles C. Foti, Jr., remind investors that they have until
May 29, 2018 to file lead plaintiff applications in a securities
class action lawsuit against Celgene Corporation (NasdaqGS: CELG), if
they purchased the Company’s shares between September 12, 2016 and
February 27, 2018, inclusive (the “Class Period”). This action is
pending in the United States District Court for the District of New
Jersey.
Apr 20, 2018 03:30 pm ET
EQUITY ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Celgene Corporation of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 29, 2018 – CELG
The following statement is being issued by Levi & Korsinsky, LLP:
Apr 19, 2018 05:51 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Celgene Corporation (CELG) and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. reminds investors that a class action
lawsuit has been filed in the U.S. District Court for the District of
New Jersey on behalf of all persons or entities who purchased or
otherwise acquired Celgene Corporation (NASDAQ:CELG) securities between
September 12, 2016 and February 27, 2018 (the “Class Period”). Investors
have until May 29, 2018 to apply to the Court to be appointed as lead
plaintiff in the lawsuit.
Apr 19, 2018 07:48 am ET
Celgene Corporation Announces Changes to Its Board of Directors
Celgene Corporation (NASDAQ:CELG) today announced changes to its Board
of Directors. Gilla Kaplan, Ph.D., Celgene’s longest-standing Director,
is retiring from the Board and will not stand for reelection at the
upcoming Annual Meeting of Stockholders to be held on June 13, 2018.
Patricia “Pat” Hemingway Hall and Hans Bishop have been elected to
Celgene’s Board of Directors.
Apr 17, 2018 07:35 am ET
New Research: Key Drivers of Growth for Johnson & Johnson, Chesapeake Energy, Visa, Celgene, Adobe, and Markel — Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, April 17, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Johnson & Johnson (NYSE:JNJ), Chesapeake Energy...
Apr 17, 2018 07:30 am ET
Celgene Corporation to Webcast at Upcoming Investor Conferences
Celgene Corporation (NASDAQ: CELG) plans to present at three upcoming
investor conferences where Celgene management will provide an overview
of the Company. The conferences will be webcast live and will be
available in the Investor Relations section of the Company’s website at www.celgene.com.
Apr 16, 2018 03:09 pm ET
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Celgene Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 29, 2018 – CELG
NEW YORK, April 16, 2018 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:
Apr 13, 2018 10:50 pm ET
CELGENE SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Celgene Corporation - CELG
NEW ORLEANS, April 13, 2018 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until May 29, 2018 to file lead plaintiff applications in a securities class action lawsuit against Celgene Corporation (NasdaqGS:CELG),...
Apr 12, 2018 02:49 pm ET
The Klein Law Firm Reminds Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Celgene Corporation
The Klein Law Firm announces the commencement of an investigation of
Celgene Corporation (NASDAQGS: CELG) concerning possible violations of
federal securities laws.
Apr 12, 2018 06:00 am ET
INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Celgene Corporation To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Ac
The securities litigation law firm of Brower Piven, A Professional
Corporation, announces that a class action lawsuit has been commenced in
the United States District Court for the District of New Jersey on
behalf of purchasers of Celgene Corporation (Nasdaq: CELG) (“Celgene” or
the “Company”) securities during the period between September 12, 2016
and February 27, 2018, inclusive (the “Class Period”). Investors who
wish to become proactively involved in the litigation have until May 29,
2018 to seek appointment as lead plaintiff.
Apr 09, 2018 04:15 pm ET
The Klein Law Firm Notifies Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Celgene Corporation (CELG)
The Klein Law Firm announces the commencement of an investigation of
Celgene Corporation (NASDAQGS:CELG) concerning possible violations of
federal securities laws.
Apr 09, 2018 07:30 am ET
Celgene Corporation to Announce First Quarter 2018 Results on May 04, 2018
Celgene Corporation (NASDAQ: CELG) will host a conference call and live
audio webcast on Friday, May 04, 2018 at 9 a.m. ET to discuss first
quarter 2018 financial and operational results. The first quarter
results will include the financial and operational results of Juno
Therapeutics, Inc. following the March 6, 2018 close of the acquisition.
The webcast can be accessed from the Investor Relations page at
Apr 06, 2018 10:50 pm ET
CELGENE SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Ce
NEW ORLEANS, April 6, 2018 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until May 29, 2018 to file lead plaintiff applications in a securities class action lawsuit against Celgene Corporation (NasdaqGS: CELG), if they purchased the Company's shares between September 12, 2016 and February 27, 2018, inclusive (the "Class Period"). This action is pending in the United States District Court for the District of New Jersey.
Apr 06, 2018 04:30 pm ET
Hagens Berman Alerts Investors in Celgene Corporation to the May 29, 2018 Lead Plaintiff Deadline in the Pending Securities Class Action and to the Abrupt Departure of Celgene’s President
SAN FRANCISCO, April 06, 2018 (GLOBE NEWSWIRE) -- Hagens Berman Sobol Shapiro LLP alerts investors in Celgene Corporation (NASDAQ:CELG) to the May 29, 2018 Lead Plaintiff deadline in the securities class action pending in the United States District...
Apr 06, 2018 07:30 am ET
CELG INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation on Behalf of Celgene Corporation Investors
Law Offices of Howard G. Smith continues its investigation on behalf of
Celgene Corporation (“Celgene” or the “Company) (NASDAQ: CELG)
investors concerning the Company and its officers’ possible violations
of federal securities laws.
Apr 05, 2018 06:00 pm ET
CELG INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Celgene Corporation
The Law Offices of Vincent Wong notifies investors of an investigation
concerning whether Celgene Corporation (“Celgene” or the “Company”)
(NASDAQGS: CELG) violated federal securities laws.
Apr 05, 2018 02:02 pm ET
Long-Term Celgene (CELG) Investors: Johnson Fistel Investigates Celgene Corporation; Encourages Long-Term Investors to Contact the Firm
SAN DIEGO, April 5, 2018 /PRNewswire/ -- Johnson Fistel, LLP is investigating potential violations of the federal and state securities laws by Celgene Corporation, (NASDAQ: CELG) ("Celgene") and certain of its officers.
Apr 05, 2018 10:30 am ET
Glancy Prongay & Murray LLP Continues Investigation on Behalf of Celgene Corporation Investors (CELG)
Glancy
Prongay & Murray LLP (“GPM”) continues its investigation on
behalf of Celgene Corporation (“Celgene” or the “Company) (NASDAQ:
Apr 04, 2018 04:40 pm ET
CELG INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Celgene Corporation Investors
Law Offices of Howard G. Smith announces an investigation on behalf of
Celgene Corporation (“Celgene” or the “Company) (NASDAQ: CELG)
investors concerning the Company and its officers’ possible violations
of federal securities laws.
Apr 04, 2018 02:34 pm ET
CELG SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Celgene Corporation
The Law Offices of Vincent Wong notifies investors of an investigation
concerning whether Celgene Corporation (“Celgene” or the “Company”)
(NASDAQGS:CELG) violated federal securities laws.
Apr 03, 2018 08:03 pm ET
Glancy Prongay & Murray LLP Announces Investigation on Behalf of Celgene Corporation Investors (CELG)
Glancy
Prongay & Murray LLP (“GPM”) announces an investigation on
behalf of Celgene Corporation (“Celgene” or the “Company) (NASDAQ:
Apr 03, 2018 04:45 pm ET
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Celgene Corporation
Levi & Korsinsky announces it has commenced an investigation of Celgene
Corporation (“Celgene” or “the Company”) (NASDAQGS: CELG) concerning
possible violations of federal securities laws.
Apr 03, 2018 04:24 pm ET
CELGENE INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Celgene Corporation To Contact The Firm
NEW YORK, April 3, 2018 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Celgene Corporation ("Celgene" or the "Company") (NASDAQ: CELG).
Apr 03, 2018 10:00 am ET
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Celgene Corporation (CELG) and Lead Plaintiff Deadline: May 29, 2018
NEW YORK, April 03, 2018 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed Celgene Corporation (“Celgene” or the “Company”) (NASDAQ:CELG) and certain of its officers, on behalf of shareholders who...
Apr 02, 2018 04:31 pm ET
Celgene Corporation Announces Departure of President and Chief Operating Officer Scott A. Smith
Celgene Corporation (NASDAQ: CELG) today announced that Scott A. Smith,
President and Chief Operating Officer, is leaving the company effective
immediately. His primary responsibilities will be assumed by Chairman
and Chief Executive Officer Mark J. Alles.
Apr 02, 2018 03:57 pm ET
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Celgene Corporation
Levi & Korsinsky announces it has commenced an investigation of Celgene
Corporation (“Celgene” or “the Company”) (NASDAQGS:CELG) concerning
possible violations of federal securities laws.
Apr 02, 2018 02:53 pm ET
SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Celgene Corporation (Nasdaq: CELG) To Contact B
STEVENSON, Md., April 02, 2018 (GLOBE NEWSWIRE) -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of...
Mar 30, 2018 10:50 pm ET
CELGENE SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Ce
NEW ORLEANS, March 30, 2018 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until May 29, 2018 to file lead...
Mar 30, 2018 01:35 pm ET
Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Celgene Corporation (CELG) and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. announces that a class action lawsuit has
been filed in the U.S. District Court for the District of New Jersey on
behalf of all persons or entities who purchased or otherwise acquired
Celgene Corporation (NASDAQ: CELG) securities between September 12, 2016
and February 27, 2018 (the “Class Period”). Investors have until May 29,
2018 to apply to the Court to be appointed as lead plaintiff in the
lawsuit.
Mar 30, 2018 10:15 am ET
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Celgene Corporation (CELG) and Lead Plaintiff Deadline: May 29, 2018
NEW YORK, March 30, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Celgene Corporation ("Celgene" or the "Company") (NASDAQ: CELG) and certain of its officers, on behalf of shareholders who purchased Celgene securities between September 12, 2016 and February 27, 2018, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: http://www.bgandg.com/celg.
Mar 29, 2018 10:00 pm ET
Robbins Geller Rudman & Dowd LLP Files Class Action Suit against Celgene Corporation
Robbins
Geller Rudman & Dowd LLP (“Robbins Geller”) (http://ww
Mar 21, 2018 09:30 am ET
S&P 500 Q4 2017 Buybacks Rose 6.0% to $137.0 Billion; Full-Year 2017 Fell 3.2% to $519.4 Billion
NEW YORK, March 21, 2018 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") today announced preliminary results indicating that S&P 500® stock buybacks, or share repurchases, totaled $137.0 billion for Q4 2017. This is a 6.0% increase from the $129.2 billion reported for Q3 2017 and a 1.2% increase from the $135.3 billion reported for Q4 2016.
Mar 20, 2018 04:05 pm ET
Prothena Announces Global Neuroscience Research & Development Collaboration with Celgene for Novel Therapies for Patients with Neurodegenerative Diseases
DUBLIN, Ireland, March 20, 2018 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel therapies in the neuroscience and orphan categories, today announced a global collaboration...
Mar 20, 2018 02:51 pm ET
Mar 06, 2018 07:30 am ET
Celgene Completes Acquisition of Juno Therapeutics, Inc., Advancing Global Leadership in Cellular Immunotherapy
Celgene Corporation (NASDAQ:CELG) today announced that it has completed
the acquisition of Juno Therapeutics, Inc. As a result, the common stock
of Juno will no longer be listed for trading on the NASDAQ Global Select
Market.
Mar 05, 2018 07:30 am ET
Celgene Announces Expiration of Cash Tender Offer for Shares of Juno Therapeutics, Inc.
Celgene Corporation (NASDAQ:CELG) today announced that its tender offer
to purchase any and all issued and outstanding shares of common stock of
Juno Therapeutics, Inc. at a price of $87.00 per share, net to the
seller in cash, without interest and less required withholding taxes,
expired at 12:00 midnight ET, at the end of the day on Friday, March 2,
2018.
Mar 01, 2018 09:10 am ET
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Celgene Corporation (CELG)
NEW YORK, March 1, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Celgene Corporation ("Celgene" or the "Company") (NASDAQ: CELG). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/celg.
Feb 27, 2018 04:30 pm ET
Celgene Provides Regulatory Update on Ozanimod for the Treatment of Relapsing Multiple Sclerosis
Celgene Corporation (NASDAQ:CELG) today announced that it has received a
Refusal to File letter from the United States Food and Drug
Administration (FDA) regarding its New Drug Application (NDA) for
ozanimod in development for the treatment of patients with relapsing
forms of multiple sclerosis. Ozanimod is a novel, oral, selective
sphingosine 1-phosphate 1 (S1PR1) and 5 (S1PR5) receptor modulator.
Feb 27, 2018 07:30 am ET
Celgene Corporation to Webcast at Upcoming Investor Conferences
Celgene Corporation (NASDAQ:CELG) plans to present at two upcoming
investor conferences where Celgene management will provide an overview
of the Company. The conferences will be webcast live and will be
available in the Investor Relations section of the Company’s website at www.celgene.com.
Feb 21, 2018 07:30 am ET
Celgene Receives Antitrust Clearance for Juno Acquisition
Celgene Corporation (NASDAQ:CELG) today announced that the applicable
waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of
1976 ("HSR") with respect to the previously announced tender offer by
Celgene’s wholly owned subsidiary, Blue Magpie Corporation, for all
issued and outstanding shares of common stock of Juno Therapeutics, Inc.
(NASDAQ:JUNO) for $87.00 per share, net to the seller in cash, without
interest and less required withholding taxes, and subsequent merger of
Blue Magpie with Juno, expired at 11:59 p.m. ET on Febr
Feb 17, 2018 04:00 pm ET
OTEZLA® (Apremilast) Phase III Data Showed Significant Improvements in Patients with Active Behçet’s Disease with Oral Ulcers
Celgene Corporation (NASDAQ:CELG) today announced that data from the
phase III RELIEF™ clinical trial of OTEZLA® (apremilast) in
patients with active Behçet’s Disease with oral ulcers were presented in
a late-breaking oral presentation at the 2018 American Academy of
Dermatology (AAD) Annual Meeting. The results showed statistically
significant reductions in oral ulcers with apremilast 30 mg twice daily
(BID) versus placebo through week 12. OTEZLA (apremilast) is Celgene’s
oral selective inhibitor of phosphodiesterase 4 (PDE4).
Feb 15, 2018 11:00 am ET
Celularity Announces $250M in Funding to Deliver Treatments for Cancer, Inflammatory and Degenerative Diseases, and Functional Regeneration
WARREN, N.J., Feb. 15, 2018 /PRNewswire/ -- Celularity has been created through the contribution and acquisition of extensive intellectual property, clinical-stage assets, basic and clinical research, and product development expertise including:
Feb 15, 2018 09:30 am ET
OTEZLA® (Apremilast) Phase II Data Showed Clinically Meaningful Improvements in Patients with Active Ulcerative Colitis
Celgene Corporation (NASDAQ:CELG) announced that data from a randomized,
placebo-controlled, multi-center, phase II clinical trial of apremilast
in patients with active ulcerative colitis who had failed at least one
conventional therapy but were naïve to biologic therapy were presented
in an oral session today at the 13th Congress of ECCO in
Vienna (Abstract OP006, 3:30 p.m. CET). The results showed that a higher
proportion of patients taking apremilast 30 mg twice daily (BID)
achieved clinical remission versus placebo (nominally sign
Feb 15, 2018 07:30 am ET
Celgene Corporation Elects John Weiland to Its Board of Directors
Celgene Corporation (NASDAQ: CELG) today announced the election of John
Weiland to its Board of Directors. Mr. Weiland has over 30 years in the
healthcare industry and was most recently the President and Chief
Operating Officer of C. R. Bard, Inc. (Bard), with worldwide
responsibility for all of Bard's business operations prior to it being
acquired by Becton, Dickinson and Company (BD) in December 2017.
Feb 14, 2018 07:30 am ET
Celgene Announces Additional $5 Billion Share Repurchase Authorization
Celgene Corporation (NASDAQ: CELG) today announced the Company's Board
of Directors authorized the repurchase of an additional $5 billion of
the Company's common stock. This open-ended program is effective
immediately. Purchases may be made in the open market or in privately
negotiated transactions from time to time, as determined by Celgene's
management and in accordance with the requirements of the Securities and
Exchange Commission.
Feb 09, 2018 07:30 am ET
Celgene Prices $4.5 Billion of Senior Unsecured Notes
Celgene Corporation (NASDAQ:CELG) today announced the successful pricing
of four series of senior unsecured notes for an aggregate principal
amount of $4.5 billion. Of these notes, $500 million will mature in 2021
and will bear interest at an annual rate of 2.875 percent, $1.0 billion
will mature in 2023 and will bear interest at an annual rate of 3.25
percent, $1.5 billion will mature in 2028 and will bear interest at an
annual rate of 3.90 percent and $1.5 billion will mature in 2048 and
will bear interest at an annual rate of 4.55 percent. Th
Feb 08, 2018 08:55 am ET
Celgene Announces Offering of Senior Unsecured Notes
Celgene Corporation (NASDAQ:CELG) today announced its intention
to offer, subject to market and other conditions, senior unsecured notes
under a shelf registration statement on Form S-3 on file with the
Securities and Exchange Commission. The interest rate, the maturity
dates and other key terms of the offering are to be determined at the
time of pricing.
Feb 06, 2018 07:30 am ET
Celgene Corporation Announces Positive Results from the Pivotal Phase III ‘OPTIMISMM’ Study of POMALYST/IMNOVID® for the Treatment of Relapsed or Refractory Multiple Myeloma
Celgene Corporation (NASDAQ:CELG) today announced that the Phase III,
randomized, open-label, international clinical study, OPTIMISMM,
achieved its primary endpoint, showing a statistically significant and
clinically meaningful improvement in progression-free survival (PFS) for
the pomalidomide arm versus the comparator arm.
Feb 02, 2018 08:00 am ET
Investor Expectations to Drive Momentum within Connecticut Water Service, Datawatch, Cadiz, Celgene, Texas Instruments, and Newfield Exploration — Discovering Underlying Factors of Influence
NEW YORK, Feb. 02, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Connecticut Water Service, Inc. (NASDAQ:CTWS), Datawatch...
Feb 02, 2018 07:30 am ET
Celgene Corporation Commences Tender Offer for Juno Therapeutics, Inc.
Celgene Corporation (NASDAQ:CELG) today announced that its wholly-owned
subsidiary, Blue Magpie Corporation, has commenced its previously
announced tender offer for all outstanding shares of common stock of
Juno Therapeutics, Inc. (NASDAQ: JUNO) at a price of $87.00 per share,
net to the seller in cash, without interest and less required
withholding taxes. The tender offer is being made in connection with the
Agreement and Plan of Merger, dated January 21, 2018, by and among
Celgene, Blue Magpie Corporation and Juno.
Feb 01, 2018 07:30 am ET
Celgene Corporation to Webcast at Upcoming Investor Conferences
Celgene Corporation (NASDAQ: CELG) plans to present at two upcoming
investor conferences where Celgene management will provide an overview
of the Company. The conferences will be webcast live and will be
available in the Investor Relations section of the Company’s website at www.celgene.com.
Jan 29, 2018 10:54 am ET
Celgene Announces Retirement of Executive Chairman Bob Hugin and Appointment of CEO Mark Alles as Chairman of the Board of Directors
Celgene Corporation (NASDAQ:CELG) today announced that Executive
Chairman Bob Hugin has decided to retire from Celgene after 19 years of
service and to step down from the Celgene Board of Directors, effective
February 5, 2018. Chief Executive Officer Mark Alles has been appointed
to the additional role of Chairman of the Board of Directors.
Jan 25, 2018 07:30 am ET
Celgene Reports Fourth Quarter and Full-Year 2017 Operating and Financial Results
Celgene Corporation (NASDAQ:CELG) reported operating results for the
fourth quarter and full year of 2017. For the fourth quarter of 2017,
net product sales were $3,479 million, an increase of 17 percent,
year-over-year. Fourth quarter total revenue increased 17 percent to
$3,483 million.
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.